Company: SCLXW
Filing Date: 2025-05-07
Form Type: POS AM
Source: 0001193125-25-115095
Chunk: 12

Company: Scilex Holding Co
Filing Date: 2025-05-07
Form: POS AM
Chunk 12
---
 ability to attract and retain qualified directors, officers, employees and key personnel; |

| • |     | our ability to compete effectively in a highly competitive market; |

| • |     | the competition from larger biotechnology companies that have greater resources, technology, relationships and/or expertise; |

| • |     | the ability to protect and enhance our corporate reputation and brand; |

| • |     | the impact from future regulatory, judicial and legislative changes in our industry; |

| • |     | our ability to obtain and maintain regulatory approval of any of our products and product candidates; |

| • |     | our ability to research, discover and develop additional product candidates; |

| • |     | our ability to grow and manage growth profitably; |

| • |     | our ability to obtain and maintain intellectual property protection and not infringe on the rights of others; |

2

| • |     | our ability to execute our business plans and strategy; |

| • |     | our ability to prevent, respond to, and recover from a cybersecurity incident; |

| • |     | the effect of global economic and political developments, including the conflicts in Ukraine and Israel; and |

| • |     | other factors detailed under the section of this prospectus titled “Risk Factors.” |

Should one or more of these risks or uncertainties materialize or should any of the assumptions made by our management prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. There may be additional risks that we consider immaterial or which are unknown. It is not possible to predict or identify all such risks. We do not undertake any obligation to update, add or to otherwise correct any forward-looking statements contained herein to reflect events or circumstances after the date they were made, whether as a result of new information, future events, inaccuracies that become apparent after the date hereof or otherwise, except as may be required under applicable securities laws. 3

CERTAIN DEFINED TERMS

| • |     | “April 2024 RDO Common Warrants” means the warrants to purchase up to an aggregate of 428,572 shares of our Common Stock at an exercise price of $38.50 per share, issued to the investor named in and pursuant to the April 2024 RDO Purchase Agreement. |

| • |     | “April 2024 RDO Placement Agent Warrants” means the warrants to purchase up to an aggregate of 34,286 shares of our Common Stock at an exercise price of